| 1 | Évaluation globale standardisée systématique des rhumatismes inflammatoires chroniques : intérêts et limites | 0.0 | 0 | Citations (PDF) |
| 2 | Subclinical psoriatic arthritis and disease interception—where are we in 2024? | 2.0 | 15 | Citations (PDF) |
| 3 | Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial | 12.4 | 13 | Citations (PDF) |
| 4 | Impact of Risk Factors on <scp>COVID</scp>‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the <scp>COVID</scp>‐19 Global Rheumatology Alliance Registry | 3.0 | 8 | Citations (PDF) |
| 5 | Ten-year clinical outcome of recent-onset axial spondyloarthritis: Results from the DESIR inception Cohort | 2.3 | 16 | Citations (PDF) |
| 6 | Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis | 4.2 | 4 | Citations (PDF) |
| 7 | Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis | 4.2 | 6 | Citations (PDF) |
| 8 | Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose? | 4.2 | 3 | Citations (PDF) |
| 9 | Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL | 4.2 | 26 | Citations (PDF) |
| 10 | Is the patient-perceived impact of psoriatic arthritis a global concept? An international study in 13 Arab countries (TACTIC study) | 2.7 | 6 | Citations (PDF) |
| 11 | Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis | 12.4 | 54 | Citations (PDF) |
| 12 | Improvements in <scp>Patient‐Reported</scp> Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial | 3.0 | 2 | Citations (PDF) |
| 13 | Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study | 4.2 | 10 | Citations (PDF) |
| 14 | Standardized reporting for systematic global evaluation of axial spondyloarthritis: An evidence-based and consensus-driven initiative | 2.3 | 0 | Citations (PDF) |
| 15 | Disease activity and widespread pain are main contributors to patient-reported global health in axial spondyloarthritis: an analysis of 6064 patients | 2.7 | 9 | Citations (PDF) |
| 16 | Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage | 4.2 | 22 | Citations (PDF) |
| 17 | Patient research partner involvement in rheumatology research: a systematic literature review informing the 2023 updated EULAR recommendations for the involvement of patient research partners | 12.4 | 6 | Citations (PDF) |
| 18 | Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies | 2.0 | 5 | Citations (PDF) |
| 19 | Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry | 12.4 | 5 | Citations (PDF) |
| 20 | Unmet needs in psoriatic arthritis, a narrative review | 0.8 | 7 | Citations (PDF) |
| 21 | Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort | 4.2 | 1 | Citations (PDF) |
| 22 | Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52‐Week Results From Two Phase 3 Studies | 1.9 | 2 | Citations (PDF) |
| 23 | Association Between Achievement of Clinical Disease Control and Improvement in Patient‐Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 <scp>SELECT</scp>‐<scp>PsA</scp> 1 and 2 Randomized Controlled Trials | 1.9 | 3 | Citations (PDF) |
| 24 | Barriers to, Facilitators of, and Interventions to Support Treat‐to‐Target Implementation in Rheumatoid Arthritis: A Systematic Review | 3.0 | 5 | Citations (PDF) |
| 25 | Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial | 12.4 | 7 | Citations (PDF) |
| 26 | Patients with axial spondyloarthritis reported willingness to use remote care and showed high adherence to electronic patient-reported outcome measures: an 18-month observational study | 2.7 | 5 | Citations (PDF) |
| 27 | Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies | 2.2 | 10 | Citations (PDF) |
| 28 | Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis | 2.0 | 13 | Citations (PDF) |
| 29 | Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE | 2.0 | 13 | Citations (PDF) |
| 30 | Development and Validation of a Self-Administered Questionnaire Measuring Essential Knowledge in Patients With Axial Spondyloarthritis | 2.4 | 9 | Citations (PDF) |
| 31 | Women With Psoriatic Arthritis Experience Higher Disease Burden Than Men: Findings From a Real-World Survey in the United States and Europe | 2.4 | 29 | Citations (PDF) |
| 32 | Impact of Physician-Defined Flares on Quality of Life and Work Impairment: An International Survey of 2238 Patients With Psoriatic Arthritis | 2.4 | 3 | Citations (PDF) |
| 33 | Challenges in interpreting sacroiliac magnetic resonance imaging for the diagnosis of axial spondyloarthritis | 2.3 | 3 | Citations (PDF) |
| 34 | Association Between Race/Ethnicity and <scp>COVID</scp>‐19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the <scp>COVID</scp>‐19 Global Rheumatology Alliance | 3.0 | 17 | Citations (PDF) |
| 35 | Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study | 12.4 | 18 | Citations (PDF) |
| 36 | Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data | 2.0 | 18 | Citations (PDF) |
| 37 | Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries | 12.4 | 16 | Citations (PDF) |
| 38 | Influence of Sex on Early Axial Spondyloarthritis: A<scp>Six‐Year</scp>Longitudinal Analysis From a Large National Cohort | 3.0 | 6 | Citations (PDF) |
| 39 | Work-Related Issues and a High Burden of Disease Are Frequent in Axial Spondyloarthritis: What Should We Be Doing Better? | 2.4 | 2 | Citations (PDF) |
| 40 | Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study | 4.2 | 3 | Citations (PDF) |
| 41 | Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce | 4.2 | 29 | Citations (PDF) |
| 42 | Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group | 2.4 | 13 | Citations (PDF) |
| 43 | Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study | 12.4 | 34 | Citations (PDF) |
| 44 | Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study | 4.2 | 14 | Citations (PDF) |
| 45 | Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: <scp>Long‐Term</scp> Results of Two Phase <scp>III</scp> Randomized Controlled Trials | 3.0 | 14 | Citations (PDF) |
| 46 | Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis | 2.0 | 5 | Citations (PDF) |
| 47 | COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance | 2.4 | 9 | Citations (PDF) |
| 48 | Exploring remission concept in axial spondyloarthritis through the perception of rheumatologists using vignettes and priority ratings | 2.0 | 4 | Citations (PDF) |
| 49 | Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) | 12.4 | 85 | Citations (PDF) |
| 50 | 2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis | 2.3 | 97 | Citations (PDF) |
| 51 | Actualisation 2022 des recommandations de la Société française de rhumatologie (SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite, incluant le rhumatisme psoriasique | 0.0 | 9 | Citations (PDF) |
| 52 | Correspondence on “Re‐examining remission definitions in rheumatoid arthritis: considering the <scp>28‐Joint</scp> Disease Activity Score, C‐reactive protein level and patient global assessment” by Felson et al | 1.9 | 1 | Citations (PDF) |
| 53 | Prevalence and consequences of psoriasis in recent axial spondyloarthritis: an analysis of the DESIR cohort over 6 years | 4.2 | 9 | Citations (PDF) |
| 54 | Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry | 12.4 | 159 | Citations (PDF) |
| 55 | Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study | 12.4 | 22 | Citations (PDF) |
| 56 | Efficacy of a nurse-led patient education intervention in promoting safety skills of patients with inflammatory arthritis treated with biologics: a multicentre randomised clinical trial | 4.2 | 22 | Citations (PDF) |
| 57 | Development and validation of a self-administered questionnaire measuring essential knowledge in patients with rheumatoid arthritis | 2.7 | 9 | Citations (PDF) |
| 58 | Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis | 2.0 | 21 | Citations (PDF) |
| 59 | SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry | 4.2 | 50 | Citations (PDF) |
| 60 | P260 Secukinumab in Patients With Psoriatic Arthritis and Axial Manifestations: Predictors of Response From the Double-blind, Randomised, Phase 3b MAXIMISE Trial | 2.0 | 0 | Citations (PDF) |
| 61 | Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact | 2.0 | 2 | Citations (PDF) |
| 62 | Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries | 4.2 | 9 | Citations (PDF) |
| 63 | Impact of Axial Spondyloarthritis on Quality of Life: Results From the European Map of Axial Spondyloarthritis (EMAS) Study in France | 2.4 | 3 | Citations (PDF) |
| 64 | Defining and managing flares in axial spondyloarthritis | 3.8 | 7 | Citations (PDF) |
| 65 | Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: <scp>Three‐Year</scp> Results From a Phase <scp>IIb</scp> Randomized Controlled Trial and Its <scp>Open‐Label</scp> Extension Study | 7.4 | 34 | Citations (PDF) |
| 66 | SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry | 4.2 | 11 | Citations (PDF) |
| 67 | Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task force | 4.2 | 20 | Citations (PDF) |
| 68 | Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry | 4.2 | 13 | Citations (PDF) |
| 69 | Comparing the Patient‐Reported Physical Function Outcome Measures in a Real‐Life International Cohort of Patients With Psoriatic Arthritis | 3.0 | 12 | Citations (PDF) |
| 70 | Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients | 12.4 | 44 | Citations (PDF) |
| 71 | Attainment of the Patient-acceptable Symptom State in 548 patients with rheumatoid arthritis: Influence of demographic factors | 2.3 | 9 | Citations (PDF) |
| 72 | Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA) | 2.0 | 30 | Citations (PDF) |
| 73 | Gender differences in patient journey to diagnosis and disease outcomes: results from the European Map of Axial Spondyloarthritis (EMAS) | 2.4 | 44 | Citations (PDF) |
| 74 | Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients | 4.2 | 15 | Citations (PDF) |
| 75 | The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review | 2.6 | 100 | Citations (PDF) |
| 76 | What influences patients’ opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study | 2.0 | 7 | Citations (PDF) |
| 77 | Critères d’évaluation à collecter pour optimiser la prise en charge de routine de la spondyloarthrite axiale : proposition fondée sur des preuves et une rencontre d’experts | 0.0 | 0 | Citations (PDF) |
| 78 | SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study | 10.7 | 35 | Citations (PDF) |
| 79 | Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial | 12.4 | 95 | Citations (PDF) |
| 80 | Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry | 12.4 | 196 | Citations (PDF) |
| 81 | Les déterminants des troubles du sommeil dans le rhumatisme psoriasique : étude observationnelle portant sur 696 patients de 14 pays | 0.0 | 0 | Citations (PDF) |
| 82 | Numérique et activités physiques en rhumatologie | 0.0 | 0 | Citations (PDF) |
| 83 | Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results | 12.4 | 28 | Citations (PDF) |
| 84 | Freins et croyances en rhumatologie dans la pratique de l’activité physique | 0.0 | 0 | Citations (PDF) |
| 85 | Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis | 4.2 | 19 | Citations (PDF) |
| 86 | Outcome measures used in psoriatic arthritis registries and cohorts: A systematic literature review of 27 registries or 16,183 patients | 3.9 | 18 | Citations (PDF) |
| 87 | Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52 | 2.4 | 2 | Citations (PDF) |
| 88 | Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases | 10.7 | 48 | Citations (PDF) |
| 89 | Young people’s perspectives on patient-reported outcome measures in inflammatory arthritis: results of a multicentre European qualitative study from a EULAR task force | 4.2 | 12 | Citations (PDF) |
| 90 | Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry | 12.4 | 586 | Citations (PDF) |
| 91 | Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial | 12.4 | 157 | Citations (PDF) |
| 92 | Wearable activity trackers and artificial intelligence in the management of rheumatic diseases | 0.8 | 22 | Citations (PDF) |
| 93 | Influence of perceived barriers and facilitators for physical activity on physical activity levels in patients with rheumatoid arthritis or spondyloarthritis: a cross-sectional study of 150 patients | 2.2 | 17 | Citations (PDF) |
| 94 | Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study | 10.7 | 45 | Citations (PDF) |
| 95 | Machine learning approaches to improve disease management of patients with rheumatoid arthritis: review and future directions | 3.7 | 25 | Citations (PDF) |
| 96 | Evaluation of the Implementation of Guidelines on the Treatment of Osteoporosis in Patients with Rheumatoid Arthritis | 2.4 | 5 | Citations (PDF) |
| 97 | Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR) | 2.0 | 25 | Citations (PDF) |
| 98 | Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients | 2.4 | 15 | Citations (PDF) |
| 99 | Criteria for inclusion in programs of functional restoration for chronic low back pain: Pragmatic Study | 3.7 | 5 | Citations (PDF) |
| 100 | Spinal-pelvic orientation: potential effect on the diagnosis of spondyloarthritis | 2.0 | 4 | Citations (PDF) |
| 101 | Determinants of Patient‐Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association WithSex in 458 Patients From Fourteen Countries | 3.0 | 49 | Citations (PDF) |
| 102 | Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties | 0.9 | 7 | Citations (PDF) |
| 103 | Impact du rhumatisme psoriasique sur la qualité de vie | 0.0 | 3 | Citations (PDF) |
| 104 | Wearable Activity Trackers in the Management of Rheumatic Diseases: Where Are We in 2020? | 3.1 | 28 | Citations (PDF) |
| 105 | Development and initial validation of a questionnaire to assess facilitators and barriers to physical activity for patients with rheumatoid arthritis, axial spondyloarthritis and/or psoriatic arthritis | 2.7 | 29 | Citations (PDF) |
| 106 | Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis | 12.4 | 113 | Citations (PDF) |
| 107 | The Patient Experienced Symptom State (PESS): a patient-reported global outcome measure that may better reflect disease remission status | 2.0 | 8 | Citations (PDF) |
| 108 | Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry | 12.4 | 1,006 | Citations (PDF) |
| 109 | Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study | 3.9 | 31 | Citations (PDF) |
| 110 | EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 | 12.4 | 221 | Citations (PDF) |
| 111 | Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial | 3.9 | 14 | Citations (PDF) |
| 112 | Effectiveness of a short functional restoration program for patients with chronic low back pain: A cohort study of 193 patients | 2.3 | 5 | Citations (PDF) |
| 113 | Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis | 2.0 | 49 | Citations (PDF) |
| 114 | Recommandations pour le traitement du rhumatisme psoriasique en 2020 | 0.0 | 0 | Citations (PDF) |
| 115 | Le savoir nécessaire aux patients atteints de polyarthrite rhumatoïde ou de spondyloarthrite. Résultats d’une enquête multicentrique française auprès de professionnels de santé et de patients | 0.0 | 2 | Citations (PDF) |
| 116 | Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis | 12.4 | 85 | Citations (PDF) |
| 117 | Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries | 2.3 | 18 | Citations (PDF) |
| 118 | How COVID-19 is changing rheumatology clinical practice | 27.8 | 32 | Citations (PDF) |
| 119 | Data to be collected for an optimal management of axial spondyloarthritis in daily practice: Proposal from evidence-based and consensual approaches | 2.3 | 18 | Citations (PDF) |
| 120 | Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider | 4.2 | 31 | Citations (PDF) |
| 121 | Needs, Experiences, and Views of People With Rheumatic and Musculoskeletal Diseases on Self-Management Mobile Health Apps: Mixed Methods Study | 4.9 | 47 | Citations (PDF) |
| 122 | Essential knowledge for patients with rheumatoid arthritis or spondyloarthritis: Results of a multicentric survey in France among health professionals and patients | 2.3 | 22 | Citations (PDF) |
| 123 | Knowledge of and expectations about functional restoration programs for chronic low back pain: A mirror survey of 150 patients and 80 physicians in 2017 | 2.3 | 0 | Citations (PDF) |
| 124 | Evaluation of the performances of ‘typical’ imaging abnormalities of axial spondyloarthritis: results of the cross-sectional ILOS-DESIR study | 4.2 | 18 | Citations (PDF) |
| 125 | Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients | 4.2 | 17 | Citations (PDF) |
| 126 | Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations | 4.2 | 36 | Citations (PDF) |
| 127 | Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology | 2.4 | 82 | Citations (PDF) |
| 128 | Effet des traitements biologiques sur la fatigue dans le rhumatisme psoriasique : revue systématique de la littérature et méta-analyse | 0.0 | 0 | Citations (PDF) |
| 129 | Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale | 2.4 | 14 | Citations (PDF) |
| 130 | Similar alteration for mental and physical aspects in health-related quality of life over 5 to 8 years in 1347 patients with early arthritis and early inflammatory back pain | 4.2 | 3 | Citations (PDF) |
| 131 | Is self-assessment by patients of disease activity acceptable over the long term in rheumatoid arthritis? A 3-year follow-up of 771 patients | 2.0 | 7 | Citations (PDF) |
| 132 | The European Map of Axial Spondyloarthritis: Capturing the Patient Perspective—an Analysis of 2846 Patients Across 13 Countries | 4.4 | 92 | Citations (PDF) |
| 133 | Assessment of the adherence to disease-modifying drugs in patients with chronic inflammatory rheumatic diseases: Results of a survey of 1594 patients | 2.3 | 11 | Citations (PDF) |
| 134 | Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known? | 2.0 | 29 | Citations (PDF) |
| 135 | OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies | 2.4 | 124 | Citations (PDF) |
| 136 | Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology | 2.4 | 87 | Citations (PDF) |
| 137 | EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases | 4.2 | 94 | Citations (PDF) |
| 138 | Recommandations pour l’évaluation et l’optimisation de l’adhésion aux traitements de fond médicamenteux des rhumatismes inflammatoires chroniques : un processus basé sur des revues de la littérature et un consensus d’experts | 0.0 | 1 | Citations (PDF) |
| 139 | Impact of comorbidities on fatigue in rheumatoid arthritis patients: Results from a nurse-led program for comorbidities management (COMEDRA) | 2.3 | 30 | Citations (PDF) |
| 140 | Use of Wearable Activity Trackers to Improve Physical Activity Behavior in Patients With Rheumatic and Musculoskeletal Diseases: A Systematic Review and Meta‐Analysis | 3.0 | 95 | Citations (PDF) |
| 141 | PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials | 2.4 | 53 | Citations (PDF) |
| 142 | Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries | 12.4 | 70 | Citations (PDF) |
| 143 | Update of French society for rheumatology recommendations for managing rheumatoid arthritis | 2.3 | 111 | Citations (PDF) |
| 144 | International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group | 3.0 | 69 | Citations (PDF) |
| 145 | Actualisation des Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde | 0.0 | 25 | Citations (PDF) |
| 146 | Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensus | 2.3 | 44 | Citations (PDF) |
| 147 | Detection of Flares by Decrease in Physical Activity, Collected Using Wearable Activity Trackers in Rheumatoid Arthritis or Axial Spondyloarthritis: An Application of Machine Learning Analyses in Rheumatology | 3.0 | 130 | Citations (PDF) |
| 148 | Mobile Health Apps for Self-Management of Rheumatic and Musculoskeletal Diseases: Systematic Literature Review | 4.9 | 93 | Citations (PDF) |
| 149 | Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients | 2.4 | 15 | Citations (PDF) |
| 150 | 2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis | 2.3 | 83 | Citations (PDF) |
| 151 | Quality of life in psoriatic arthritis | 3.7 | 171 | Citations (PDF) |
| 152 | Actualisation 2018 des recommandations de la Société française de rhumatologie (SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite | 0.0 | 8 | Citations (PDF) |
| 153 | The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countries | 2.0 | 39 | Citations (PDF) |
| 154 | An e-health interactive self-assessment website (Sanoia®) in rheumatoid arthritis. A 12-month randomized controlled trial in 320 patients | 2.3 | 59 | Citations (PDF) |
| 155 | 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis | 12.4 | 57 | Citations (PDF) |
| 156 | Improving the peer review skills of young rheumatologists and researchers in rheumatology: the EMEUNET Peer Review Mentoring Program | 4.2 | 12 | Citations (PDF) |
| 157 | Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis | 2.3 | 26 | Citations (PDF) |
| 158 | Développement et validation d’un questionnaire identifiant différentes stratégies comportementales chez les patients lombalgiques chroniques | 0.0 | 0 | Citations (PDF) |
| 159 | Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice‐Based Call for a Paradigm Change | 3.0 | 97 | Citations (PDF) |
| 160 | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force | 12.4 | 582 | Citations (PDF) |
| 161 | La rémission est associée à la CRP et au tabagisme dans la spondyloarthrite axiale débutante. La cohorte DESIR | 0.0 | 0 | Citations (PDF) |
| 162 | Facteurs associés à la connaissance générale et à celle des éléments de sécurité des patients sous biothérapie pour un rhumatisme inflammatoire : étude de 677 patients | 0.0 | 1 | Citations (PDF) |
| 163 | An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS | 12.4 | 72 | Citations (PDF) |
| 164 | La place de la e-santé et les objets connectés dans le traitement de patients atteints de polyarthrite rhumatoïde | 0.0 | 1 | Citations (PDF) |
| 165 | Perception des poussées de polyarthrite rhumatoïde telles que rapportées par les patients : sous-analyse de l’essai STRASS sur les stratégies de diminution progressive du traitement | 0.0 | 0 | Citations (PDF) |
| 166 | A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative | 3.9 | 62 | Citations (PDF) |
| 167 | Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers’ effectiveness in axial spondyloarthritis: results of a prospective, multicentre study | 12.4 | 99 | Citations (PDF) |
| 168 | Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire | 12.4 | 18 | Citations (PDF) |
| 169 | Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature | 2.4 | 100 | Citations (PDF) |
| 170 | Le délai diagnostique de la spondyloarthrite axiale : étude transversale sur 432 patients | 0.0 | 0 | Citations (PDF) |
| 171 | Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider | 4.2 | 22 | Citations (PDF) |
| 172 | The effects of cultural background on patient-perceived impact of psoriatic arthritis - a qualitative study conducted in Brazil and France | 2.0 | 7 | Citations (PDF) |
| 173 | EULAR ‘points to consider’ for the conduction of workforce requirement studies in rheumatology | 4.2 | 20 | Citations (PDF) |
| 174 | Prevalence of degenerative changes and overlap with spondyloarthritis-associated lesions in the spine of patients from the DESIR cohort | 4.2 | 41 | Citations (PDF) |
| 175 | The Portuguese Rheumatoid Arthritis Impact of Disease (RAID) score and its measurement equivalence in three countries: validation study using Rasch Models | 2.1 | 8 | Citations (PDF) |
| 176 | Methods to improve medication adherence in patients with chronic inflammatory rheumatic diseases: a systematic literature review | 4.2 | 47 | Citations (PDF) |
| 177 | Fears and beliefs of people living with rheumatoid arthritis: a systematic literature review | 2.0 | 37 | Citations (PDF) |
| 178 | Physical Activity Assessment Using an Activity Tracker in Patients with Rheumatoid Arthritis and Axial Spondyloarthritis: Prospective Observational Study | 4.9 | 59 | Citations (PDF) |
| 179 | Use of nonsteroidal anti-inflammatory drugs in early axial spondyloarthritis in daily practice: Data from the DESIR cohort | 2.3 | 9 | Citations (PDF) |
| 180 | Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016 | 2.4 | 120 | Citations (PDF) |
| 181 | New GRAPPA and EULAR recommendations for the management of psoriatic arthritis | 2.0 | 38 | Citations (PDF) |
| 182 | Development and validation of a questionnaire categorizing behavioral strategies in patients with chronic low back pain | 2.3 | 3 | Citations (PDF) |
| 183 | Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1) | 12.4 | 84 | Citations (PDF) |
| 184 | Collecte et prise en charge de certaines comorbidités et facteurs de risque associés dans le cadre des rhumatismes inflammatoires chroniques dans la pratique quotidienne en France | 0.0 | 0 | Citations (PDF) |
| 185 | International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials | 12.4 | 238 | Citations (PDF) |
| 186 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update | 12.4 | 3,466 | Citations (PDF) |
| 187 | Mucopolysaccharidoses seen in adults in rheumatology | 2.3 | 21 | Citations (PDF) |
| 188 | The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission | 12.4 | 80 | Citations (PDF) |
| 189 | Disease activity trajectories in early axial spondyloarthritis: results from the DESIR cohort | 12.4 | 33 | Citations (PDF) |
| 190 | Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients | 2.0 | 76 | Citations (PDF) |
| 191 | Utilisation des anti-inflammatoires non-stéroïdiens dans la spondylarthrite axiale débutante en pratique quotidienne : données de la cohorte DESIR | 0.0 | 0 | Citations (PDF) |
| 192 | Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients | 2.2 | 55 | Citations (PDF) |
| 193 | Patient-perceived flares in rheumatoid arthritis: A sub-analysis of the STRASS treatment tapering strategy trial | 2.3 | 11 | Citations (PDF) |
| 194 | Patient-reported Flares in Ankylosing Spondylitis: A Cross-sectional Analysis of 234 Patients | 2.4 | 18 | Citations (PDF) |
| 195 | Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross‐Sectional Study of 977 Patients | 3.0 | 31 | Citations (PDF) |
| 196 | Mapping the Effect of Psoriatic Arthritis Using the International Classification of Functioning, Disability and Health | 2.4 | 35 | Citations (PDF) |
| 197 | Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial | 4.2 | 14 | Citations (PDF) |
| 198 | Flares assessed weekly in patients with rheumatoid arthritis or axial spondyloarthritis and relationship with physical activity measured using a connected activity tracker: a 3-month study | 4.2 | 42 | Citations (PDF) |
| 199 | Validating Rheumatoid Arthritis Remission Using the Patients’ Perspective: Results from a Special Interest Group at OMERACT 2016 | 2.4 | 16 | Citations (PDF) |
| 200 | Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting | 2.4 | 25 | Citations (PDF) |
| 201 | Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets | 2.4 | 35 | Citations (PDF) |
| 202 | Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts | 4.2 | 18 | Citations (PDF) |
| 203 | Diagnostic delay in axial spondyloarthritis: A cross-sectional study of 432 patients | 2.3 | 63 | Citations (PDF) |
| 204 | Remission is related to CRP and smoking in early axial spondyloarthritis. The DESIR cohort | 2.3 | 14 | Citations (PDF) |
| 205 | Factors associated with knowledge and safety skills of arthritis patients receiving biologics: A survey of 677 patients | 2.3 | 13 | Citations (PDF) |
| 206 | Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France | 2.3 | 43 | Citations (PDF) |
| 207 | Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative | 12.4 | 223 | Citations (PDF) |
| 208 | Translating patient reported outcome measures: methodological issues explored using cognitive interviewing with three rheumatoid arthritis measures in six European languages | 2.0 | 15 | Citations (PDF) |
| 209 | The Reporting of Patient-reported Outcomes in Studies of Patients with Rheumatoid Arthritis: A Systematic Review of 250 Articles | 2.4 | 45 | Citations (PDF) |
| 210 | Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting | 2.4 | 15 | Citations (PDF) |
| 211 | Physical activity in patients with axial spondyloarthritis: a cross-sectional study of 203 patients | 2.7 | 40 | Citations (PDF) |
| 212 | Amélioration des résultats rapportés par les patients atteints de polyarthrite rhumatoïde traités par rituximab : évaluation ouverte de 175 patients | 0.0 | 0 | Citations (PDF) |
| 213 | Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting | 2.4 | 25 | Citations (PDF) |
| 214 | Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations | 27.8 | 72 | Citations (PDF) |
| 215 | Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature | 4.2 | 221 | Citations (PDF) |
| 216 | Rheumatology training experience across Europe: analysis of core competences | 4.2 | 20 | Citations (PDF) |
| 217 | Prevalence of Renal Impairment in Patients With Rheumatoid Arthritis: Results From a Cross‐Sectional Multicenter Study | 3.0 | 33 | Citations (PDF) |
| 218 | Patient‐Physician Discordance in Global Assessment in Rheumatoid Arthritis: A Systematic Literature Review With Meta‐Analysis | 3.0 | 99 | Citations (PDF) |
| 219 | Fatigue in psoriatic arthritis – a cross-sectional study of 246 patients from 13 countries | 2.3 | 56 | Citations (PDF) |
| 220 | Preliminary definitions of ‘flare’ in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative | 12.4 | 58 | Citations (PDF) |
| 221 | In rheumatoid arthritis, country of residence has an important influence on fatigue: results from the multinational COMORA study | 2.0 | 26 | Citations (PDF) |
| 222 | Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis | 12.4 | 103 | Citations (PDF) |
| 223 | European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update | 12.4 | 775 | Citations (PDF) |
| 224 | Fatigue in early axial spondyloarthritis. Results from the French DESIR cohort | 2.3 | 24 | Citations (PDF) |
| 225 | Patient global assessment in psoriatic arthritis – what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study | 2.3 | 40 | Citations (PDF) |
| 226 | In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study | 12.4 | 45 | Citations (PDF) |
| 227 | Patient-physician discordance in global assessment in early spondyloarthritis and its change over time: the DESIR cohort | 12.4 | 33 | Citations (PDF) |
| 228 | Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP | 2.4 | 52 | Citations (PDF) |
| 229 | Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis | 4.2 | 108 | Citations (PDF) |
| 230 | Fatigue in Egyptian patients with rheumatic diseases: a qualitative study | 3.0 | 19 | Citations (PDF) |
| 231 | Brief Report: Nonsteroidal Antiinflammatory Drug–Sparing Effect of Tumor Necrosis Factor Inhibitors in Early Axial Spondyloarthritis: Results From the DESIR Cohort | 7.4 | 13 | Citations (PDF) |
| 232 | Impact of repeated measures of joint space width on the sample size calculation: An application to hip osteoarthritis | 2.3 | 5 | Citations (PDF) |
| 233 | Étude transversale des compétences de sécurité de 677 patients traités par biomédicament pour un rhumatisme inflammatoire | 0.0 | 0 | Citations (PDF) |
| 234 | Application of the European Society of Cardiology, Adult Treatment Panel III and American College of Cardiology/American Heart Association guidelines for cardiovascular risk management in a French cohort of rheumatoid arthritis | 2.3 | 17 | Citations (PDF) |
| 235 | A randomized controlled trial for improving patient self-assessment of synovitis in rheumatoid arthritis with education by ultrasonography: the RAEUS Study | 2.0 | 11 | Citations (PDF) |
| 236 | Differences and similarities in rheumatology specialty training programmes across European countries | 12.4 | 19 | Citations (PDF) |
| 237 | Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT | 2.4 | 9 | Citations (PDF) |
| 238 | Enhanced Patient Involvement and the Need to Revise the Core Set — Report from the Psoriatic Arthritis Working Group at OMERACT 2014 | 2.4 | 36 | Citations (PDF) |
| 239 | Outcome Domains and Measures in Total Joint Replacement Clinical Trials: Can We Harmonize Them? An OMERACT Collaborative Initiative | 2.4 | 30 | Citations (PDF) |
| 240 | EULAR recommendations for patient education for people with inflammatory arthritis | 12.4 | 331 | Citations (PDF) |
| 241 | Intra-articular injections in thumb osteoarthritis: A systematic review and meta-analysis of randomized controlled trials | 2.3 | 46 | Citations (PDF) |
| 242 | Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA) | 12.4 | 152 | Citations (PDF) |
| 243 | Version patient des recommandations de prise en charge de la polyarthrite rhumatoïde : une collaboration entre la Société française de rhumatologie et des associations de patients atteints de polyarthrite rhumatoïde | 0.0 | 1 | Citations (PDF) |
| 244 | Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis | 2.4 | 3 | Citations (PDF) |
| 245 | Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients | 2.3 | 9 | Citations (PDF) |
| 246 | Evaluation of Serum Interleukin‐6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort | 3.0 | 58 | Citations (PDF) |
| 247 | Repeated Anticitrullinated Protein Antibody and Rheumatoid Factor Assessment Is Not Necessary in Early Arthritis: Results from the ESPOIR Cohort | 2.4 | 18 | Citations (PDF) |
| 248 | Updating the OMERACT Filter: Discrimination and Feasibility | 2.4 | 22 | Citations (PDF) |
| 249 | Reporting of patient-perceived impact of rheumatoid arthritis and axial spondyloarthritis over 10 years: a systematic literature review | 2.0 | 24 | Citations (PDF) |
| 250 | How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0 | 2.4 | 89 | Citations (PDF) |
| 251 | Clinical measurement of disease activity in rheumatoid arthritis: why, how and utility of patient self-assessment | 0.4 | 0 | Citations (PDF) |
| 252 | Assessing structural changes in axial spondyloarthritis using a low-dose biplanar imaging system | 2.0 | 12 | Citations (PDF) |
| 253 | Cross-sectional study of self-care safety skills in 677 patients on biodrugs for inflammatory joint disease | 2.3 | 13 | Citations (PDF) |
| 254 | Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of “Truth”: Content, Face, and Construct Validity | 2.4 | 35 | Citations (PDF) |
| 255 | Updating the OMERACT Filter: Implications for Patient-reported Outcomes | 2.4 | 55 | Citations (PDF) |
| 256 | Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets | 2.4 | 21 | Citations (PDF) |
| 257 | Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0 | 3.7 | 713 | Citations (PDF) |
| 258 | Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis | 12.4 | 289 | Citations (PDF) |
| 259 | Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis | 12.4 | 477 | Citations (PDF) |
| 260 | Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis | 2.3 | 126 | Citations (PDF) |
| 261 | Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde | 0.0 | 12 | Citations (PDF) |
| 262 | Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis | 12.4 | 127 | Citations (PDF) |
| 263 | A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative | 12.4 | 379 | Citations (PDF) |
| 264 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update | 12.4 | 1,744 | Citations (PDF) |
| 265 | Patient Involvement in Outcome Measures for Psoriatic Arthritis | 4.4 | 39 | Citations (PDF) |
| 266 | Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force | 12.4 | 416 | Citations (PDF) |
| 267 | Reliability of joint count assessment in rheumatoid arthritis: A systematic literature review | 3.9 | 61 | Citations (PDF) |
| 268 | Updating the OMERACT Filter: Implications for Imaging and Soluble Biomarkers | 2.4 | 14 | Citations (PDF) |
| 269 | When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations | 4.1 | 25 | Citations (PDF) |
| 270 | The learning curve of nurses for the assessment of swollen and tender joints in rheumatoid arthritis | 2.3 | 17 | Citations (PDF) |
| 271 | Patient perspective in outcome measures developed by OMERACT | 0.3 | 9 | Citations (PDF) |
| 272 | Tolérance des biothérapies : élaboration et validation d’un questionnaire évaluant les compétences d’auto-gestion et de sécurité du patient : le questionnaire BioSecure. Une initiative de la Société française de rhumatologie, section Éducation thérapeutique | 0.0 | 3 | Citations (PDF) |
| 273 | Mortality in rheumatoid arthritis over the last fifty years: Systematic review and meta-analysis | 2.3 | 251 | Citations (PDF) |
| 274 | Safety of biologics: Elaboration and validation of a questionnaire assessing patients’ self-care safety skills: The BioSecure questionnaire. An initiative of the French Rheumatology Society Therapeutic Education section | 2.3 | 37 | Citations (PDF) |
| 275 | Autonomous online health assessment questionnaire registry in daily clinical practice | 2.0 | 15 | Citations (PDF) |
| 276 | Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey | 2.0 | 129 | Citations (PDF) |
| 277 | Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent? | 12.4 | 66 | Citations (PDF) |
| 278 | Assessment of work instability in spondyloarthritis: a cross-sectional study using the ankylosing spondylitis work instability scale | 2.0 | 21 | Citations (PDF) |
| 279 | A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis | 12.4 | 239 | Citations (PDF) |
| 280 | Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID) | 4.2 | 69 | Citations (PDF) |
| 281 | Abatacept therapy and safety management | 2.3 | 51 | Citations (PDF) |
| 282 | The Impact of Coping Strategies on Mental and Physical Well-Being in Patients with Rheumatoid Arthritis | 3.9 | 60 | Citations (PDF) |
| 283 | Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity | 3.0 | 158 | Citations (PDF) |
| 284 | Clinical outcomes in psoriatic arthritis: A systematic literature review | 3.0 | 54 | Citations (PDF) |
| 285 | TNF alpha antagonist therapy and safety monitoring | 2.3 | 66 | Citations (PDF) |
| 286 | On publication policy, combination therapy, and the European League Against Rheumatism recommendations for the management of rheumatoid arthritis: Comment on the article by Graudal et al | 6.0 | 1 | Citations (PDF) |
| 287 | OARSI/OMERACT Initiative to Define States of Severity and Indication for Joint Replacement in Hip and Knee Osteoarthritis. An OMERACT 10 Special Interest Group | 2.4 | 73 | Citations (PDF) |
| 288 | Tocilizumab: Therapy and safety management | 2.3 | 54 | Citations (PDF) |
| 289 | Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: Meta‐analysis of randomized controlled trials | 3.0 | 179 | Citations (PDF) |
| 290 | Relative Clinical Influence of Clinical, Laboratory, and Radiological Investigations in Early Arthritis on the Diagnosis of Rheumatoid Arthritis. Data from the French Early Arthritis Cohort ESPOIR | 2.4 | 23 | Citations (PDF) |
| 291 | Patient-Reported Outcomes in Rheumatoid Arthritis: Why are They Important and How Should They Be Assessed? | 0.1 | 13 | Citations (PDF) |
| 292 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs | 12.4 | 1,480 | Citations (PDF) |
| 293 | Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis | 12.4 | 187 | Citations (PDF) |
| 294 | Reporting of Adherence to Medication in Recent Randomized Controlled Trials of 6 Chronic Diseases: A Systematic Literature Review | 0.8 | 76 | Citations (PDF) |
| 295 | Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis | 12.4 | 24 | Citations (PDF) |
| 296 | Prediction of Work Impact in Axial Spondylarthritis by the Work Instability Scale: A Prospective Cohort Study Of 101 Patients | 2.4 | 0 | Citations (PDF) |
| 297 | Effect of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey | 2.4 | 7 | Citations (PDF) |
| 298 | EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis | 12.4 | 76 | Citations (PDF) |
| 299 | The Effectiveness of Digital Apps Providing Personalized Exercise Videos: Systematic Review With Meta-Analysis | 4.9 | 15 | Citations (PDF) |
| 300 | Follow-Up of Patients With Axial Spondyloarthritis in Specialist Health Care With Remote Monitoring and Self-Monitoring Compared With Regular Face-to-Face Follow-Up Visits (the ReMonit Study): Protocol for a Randomized, Controlled Open-Label Noninferiority Trial | 1.3 | 8 | Citations (PDF) |
| 301 | Psychometric Properties of Patient Global Assessment in Psoriatic Arthritis: A Systematic Literature Review | 2.4 | 1 | Citations (PDF) |
